MedTrace Logo

Prevention of Opioid-Induced Hypoxemia

NCT04453722 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2025-08-29

Study results available
· View outcomes & findings →

Summary

To evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO.

Conditions

  • Non-cardiac Surgery

Interventions

DEVICE

Oxalert Monitor Mode

The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.

DEVICE

Oxalert Normal mode

The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Daniel Sessler, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2022-04-30
Completion
2023-06-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453722 on ClinicalTrials.gov